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LIFESTYLE INTERVENTION VS? METFORMIN IN THE MAINTENANCE OF 
NORMOGLYCEMIA IN PREDIABETIC ADOLESCENTS 
ANNA SCHMIDT 
ABSTRACT 
Introduction 
Type 2 diabetes mellitus (T2DM), once thought to be an adult disease, now affects large 
numbers of children.  The prevalence of T2DM in children increased 35% between 2001 
and 20091 and while it appears to now be leveling off, it is clear that much of the burden 
of disease falls disproportionately on ethnic minorities.  It is well known that there are 
changes occurring in the microvasculature well before diabetes is diagnosed, and these 
changes are thought to contribute to micro- and macrovascular complications.  Therefore, 
prediabetes, which is a time of mild hyperglycemia that exists between normal glucose 
metabolism and overt diabetes, provides a target for behavior modification and 
potentially the prevention of complications.  The mainstay of treatment for diabetes has 
been lifestyle intervention and treatment with metformin.  Research has shown that both 
intensive lifestyle interventions and metformin are effective for the treatment of T2DM.  
However, much of this knowledge comes from studies on adults and is simply inferred to 
youth.  Thus, at this time it is still unknown to what extent treatments including lifestyle 
intervention and metformin should be used, or how they should be utilized, in youth.  
This is especially true for youth with prediabetes, as this is likely where prevention of the 
disease needs to occur to have the greatest overall benefit.   
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Proposed study 
Thus, the proposed study will directly compare two groups treated with standard of care 
and either metformin daily or intensive lifestyle intervention with a CrossFit™ training 
modality.  The primary outcome is treatment failure and development of diabetes.  A 
secondary outcome is achievement of normoglycemia and its durability.   
Conclusions 
This study will be the first to examine the longer term outcomes of the use of metformin 
in youth as well as the effects of high intensity functional training (HIFT) using the 
CrossFit™ modality.  While there is accumulating evidence about the safety of the use of 
metformin in youth, most studies are of short duration and this study will provide longer 
term results.  Additionally, CrossFit™, a relatively new exercise modality, has not been 
tested in the literature on youth and as a form of combined aerobic and resistance 
training, it may provide and effective and interesting means of lifestyle intervention and 
reversion to normoglycemia in adolescents.  In conclusion the results from this study will 
provide significant clinical relevance.   
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INTRODUCTION 
Background 
Type 2 diabetes mellitus (T2DM) is a disease state that exists at the end of a 
continuum2,3.  Before overt disease is identified, individuals may have glucose 
metabolism impairments with mild hyperglycemia, but not to levels required to be 
diagnosed with diabetes.  This is known as prediabetes and has been defined by the 
American Diabetes Association (ADA)4.  This designation is helpful as the prediabetic 
state puts individuals at relatively high risk for the development of diabetes as well as 
micro- and macrovascular complications2,5.  Research has confirmed that microvascular 
changes are occurring during the prediabetic state6–10 during which most individuals are 
asymptomatic11,12.  Prevention of this disease is important as it has been estimated that 
those that are diagnosed with T2DM between 15 and 24 years of age have a resultant loss 
of life expectancy of approximately 15 years, and those with early diagnoses are more 
likely to experience severe, chronic complications from T2DM by their 40s13.  The 
individual and societal costs are great, with the U.S. spending an estimated $245 billion 
on diabetes in 201214, but prevention has been shown to be helpful2,11,15–20.  It has been 
estimated that, at least in adults, the cost of treating those with prediabetes may 
significantly lower total all cause monthly health care costs16.  If these results can be 
transposed to those who are found to be prediabetic as children and adolescents, and if 
earlier treatment can be instituted, this will result in less disease with significantly less 
comorbidities and lower associated health care costs over the duration of an individual’s 
life. 
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Type 2 diabetes mellitus, has for a long time been thought of as a disease of 
adults.  However, more recently it has been recognized to also occur in children and 
adolescents.  The natural history of diabetes, which has been studied mostly in adults due 
to its increased prevalence in that population, includes a progression from normal glucose 
tolerance, to impaired fasting glucose (IFG), to impaired glucose tolerance (IGT), and 
finally overt T2DM21.  While it is understood that there is a disease continuum, it is 
uncertain where on the continuum complications begin and if it is population specific.  
Along much of the disease continuum individuals remain asymptomatic22,23 and, as the 
adult literature indicates, at some point there is microvascular damage being done 
including nephropathy, retinopathy and neuropathy24,25.  In children and adolescents it 
has been suggested that the pathophysiology of the progression of the disease from 
normoglycemia to T2DM may be different than in adults26–28, and evidence indicates that 
the natural history of T2DM in children progresses much more quickly29,30.   
In comparison to adult literature, there is an overall paucity of literature 
examining diabetes, especially prediabetes, in children.  There is surprisingly little known 
about the determinants of T2DM in children11, yet research has suggested that the disease 
becomes fulminant at an accelerated pace29,30.  This makes the need to be able to identify 
those in the earliest stages of disease essential in order to allow for the prevention of the 
accumulation of micro- and macrovascular damage and any associated complications.  
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Statement of the Problem 
Over the course of the last few decades there has been an increase in the number of 
overweight and obese children and adolescents in the United States.  The Centers for 
Disease Control (CDC) indicates that the number of obese children has more than 
doubled and that of adolescents quadrupled over the past 30 years31,32.  Along with this 
increased prevalence of obesity there has also been an increase in the number of children 
with comorbidities such as hypertension, dyslipidemia, fatty liver disease, 
musculoskeletal disorders and cardiovascular disease4,13,18, all of which are associated 
with obesity.  Similarly, the number of children that have been diagnosed with T2DM, a 
disease that used to be uncommon in this population33, has also seen a dramatic increase 
in prevalence.  Recently, the number of children and adolescents with prediabetes has 
also dramatically increased, putting this population at high risk for developing diabetes 
and ultimately complications such as cardiovascular disease5.  In a 2012 publication 
which examined National Health and Nutrition Examination Survey (NHANES) data 
from 1999-2008 it was estimated that up to 15% of adolescents had prediabetes or 
diabetes and the prevalence had increased from 9% to 23%12.  In a more recent article 
examining NHANES data from 2005-2014 it was estimated that 17.7% of adolescents 
were prediabetic.  A small number, 0.8% had diabetes, but of these 28.5% were 
undiagnosed34.  This is one of the most striking features of T2DM, where up to one third 
of individuals with the disease are unaware that they have it11. 
While the most recent numbers indicate that the prevalence of obesity in children 
and adolescents appears to be leveling off31,35, the complications associated with it are 
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just becoming clear.  The number of individuals affected is fairly large and the associated 
complications and comorbidities are quite devastating.  In a recent analysis of 
longitudinal data by The SEARCH for Diabetes in Youth (SEARCH) Research Group it 
was found that at a mean age of 22.1 years with a mean duration of 7.9 years of 
diagnosed T2DM, 72% of individuals had at least 1 complication or comorbidity 
associated with diabetes36.  These effects are far reaching, impacting not only individuals 
but also impacting society as diabetes has become a major public health concern.  The 
financial burden is great, as early diagnosis leads to longer duration of disease which 
contributes to greater comorbidities, decreased life expectancy13, and increased health 
care costs16,20. 
 Finally, while there are guidelines for clinicians to define and screen for 
prediabetes and diabetes in the pediatric population, it has been found that the application 
of these guidelines are often difficult for clinicians to put into action, especially during 
the prediabetic period.  In a study by Bailey et al. where clinicians who work closely with 
the pediatric population were surveyed, it was found that 70% of respondents fell into the 
“late intervention” group who were more likely to wait to intervene until these young 
patients were morbidly obese, had abnormal lipid profiles, required insulin, had very high 
blood pressure, or when obesity was impacting the patients mental health37.  This 
becomes a large public health burden, as the Treatment Options for type 2 Diabetes in 
Adolescents and Youth (TODAY) study26,28,29 and others30, have indicated that relatively 
rapid pathophysiological changes have already begun by the time of T2DM diagnosis.  
With these changes the restoration of normoglycemia, especially over the long term, 
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becomes very difficult to achieve even with intervention.  This leads to the conclusion 
that all efforts need to be put into place as early as possible, to achieve durable 
normoglycemia in this young population in order to prevent the undeniable consequences 
of hyperglycemia and diabetes.   
 
Hypothesis 
It is hypothesized that higher rates of treatment failure and progression to diabetes will be 
seen in the group treated with metformin than in the group treated with intensive lifestyle 
intervention.  Additionally, it is hypothesized that those undergoing intensive lifestyle 
intervention will have higher rates of return to, and more durable rates of normoglycemia 
than those in the metformin intervention.    
 
Objectives and specific aims 
The objective of this study is to determine rates of treatment failure and progression to 
T2DM.  A secondary objective is to determine how best to return to a state of 
normoglycemia and to determine, for what duration, normoglycemia can be maintained 
in individuals randomly assigned to current standard of care plus either the addition of 
lifestyle intervention (group 1) or metformin (group 2). 
The aims of the study will be accomplished through the following: 
1. The primary aim will be to determine progression to diabetes as measured 
according to ADA guidelines and via measuring fasting glucose, oral glucose 
tolerance or hemoglobin A1C 
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2. A secondary aim will be to determine how many participants are able to return to, 
and maintain, normoglycemia and for which duration they are able to do so, again 
through measuring fasting glucose, oral glucose tolerance or hemoglobin A1C
 7 
REVIEW OF THE LITERATURE 
Overview 
Diabetes mellitus is a complex metabolic disorder whose main clinical and diagnostic 
feature is hyperglycemia38.  While there is much complexity to the disorder, it eventually 
involves dysfunction of the pancreas.  The pancreas is a small organ found in the 
abdomen.  It is classified as both an exocrine organ producing digestive enzymes and as 
an endocrine organ producing a variety of hormones.  The hormones are produced by 
clusters of cells known as the islets of Langerhans.  While metabolically important, the 
islets of Langerhans only make up about 2% of the pancreas by mass.  There are various 
cell types that compose the islets of Langerhans and include α-cells which secrete 
glucagon, β-cells that secrete insulin, δ-cells that secrete somatostatin, and γ-cells that 
secrete pancreatic polypeptide. 
 
Figure 1: Anatomy of the islets of Langerhans39 
Insulin and glucagon are antagonistic hormones that play key roles in the regulation of 
blood glucose.  Insulin is secreted when blood glucose is high and stimulates cells to 
uptake glucose, fatty acids and amino acids, either for use in metabolism or for storage.  
Glucagon is secreted when blood glucose is low and stimulates gluconeogenesis in the 
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liver, glycogenolysis, and release of glucose into the blood stream to make glucose 
available for use.  It is the β-cells and the secretion of insulin that are ultimately affected 
in diabetes mellitus.   
Diabetes mellitus can be broken down into several categories which are 
distinguished based on their differences in etiology, age of onset, and pathophysiology11. 
The current categorizations, with their distinguishable characteristics and prevalence, are 
provided in Table 1. 
Table 1. Categories of Diabetes Mellitus 
Category Percent of Diabetes Distinguishable Characteristics 
Type 1 diabetes 5-10% Autoimmune 
Primarily begins in childhood 
Autoantibodies 
Type 2 diabetes 90-95% Peripheral insulin resistance 
Β-cell failure (various extent) 
Insulin deficiency 
Increased hepatic glucose output 
Gestational 
diabetes 
mellitus 
1-14% of all pregnancies Glucose intolerance with onset or first 
recognition during pregnancy 
Represents increased risk of T2DM 
for mother and fetus 
Other Up to 5% Specific genetic syndromes 
Surgery 
Drugs 
Malnutrition 
Infection and other illnesses 
Prediabetes U.S. Population Estimates: 
Adults: 86 million40  
Adolescents*:approximately 
4 million 
Typically asymptomatic, but where 
initiation of suspected microvascular 
changes occur 
Table based on11 and 6–10; *Adolescents population estimated from NHANES 2005-
201434 and number of adolescents 12-17 in US in 201441 
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History 
While diabetes has been recognized since the times of the ancient Greeks, it wasn’t until 
the beginning of the 20th century that people began to understand the disease as we do 
today.  It was first recognized in the 1920s that insulin, or the lack there of, played a key 
role in the disease.  While as early as the 1930s it was understood that there were 
differences in disease states with some being “insulin-dependent” while others were 
“non-insulin dependent”, it wasn’t until 1979 that type 1 and type 2 diabetes were 
defined38.  
As indicated, diabetes is a disease which results in hyperglycemia.  Current 
diagnosis of diabetes is based on checking an individual’s blood for normoglycemia or 
hyperglycemia with criteria for normal, prediabetic and diabetic in Table 2.  
Hyperglycemia occurs on a spectrum from normal to high blood sugars.  Those with 
adequately high blood sugars are considered diabetic.  However, there are those that are 
no longer able to maintain normoglycemia but have not quite reached blood sugar levels 
to be able to classify them as diabetic and are instead considered prediabetic. The three 
tests that are used for evaluation include fasting plasma glucose (FPG), an oral glucose 
tolerance test (OGTT), or the hemoglobin A1C (A1C).  While the first two tests directly 
measure an individual’s blood glucose, the A1C provides a measure of hyperglycemia 
over a two to three month duration.  This occurs by measuring glycated hemoglobin, a 
product of glucose attaching to hemoglobin.  Each of these tests has its own benefits and 
limitations and while the ADA indicates that the tests are equally appropriate for 
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diagnosis, they also note that the tests do not necessarily detect diabetes in the same 
individuals4.    
Table 2. 2017 ADA Criteria for Diagnosis of Normal Glucose, Prediabetes and 
Diabetes 
Test Normal Prediabetes Diabetes 
Fasting Plasma Glucose, mg/dL < 100 100-125 > 125 
Oral Glucose Tolerance, mg/dL < 140 140-199 > 199 
Hemoglobin A1C, % < 5.7 5.6-6.4 ≥ 6.5 
 
Pathophysiology 
While type 1 and type 2 diabetes are both diseases of metabolism and ultimately impaired 
insulin secretion, their etiologies are strikingly different.  Type 1 diabetes mellitus has 
been fairly well studied and is well recognized as having an autoimmune etiology 
characterized by β-cell destruction, while its primary cause is still unknown38.  In the 
1960s and 70s T1DM was linked to inflammation within the islets of Langerhans and 
destruction by autoantibodies38.  Until the late 1970s, this was referred to as “insulin 
dependent” diabetes due to the necessity of exogenous insulin.  Diagnosis has classically 
occurred in youth and has been associated with a genetically predisposed individual who 
is exposed to an early life environmental trigger that activates a self-targeting immune 
cascade38.  What these initial triggers are, while speculation exists about infections, 
nutrition and chemicals, is still unknown38.  Antibodies to components of the islets are 
commonly identified with one or more being diagnostic for T1DM4. 
In contrast to T1DM, T2DM has historically been a disease of adults.  It has only 
relatively recently been recognized to occur in children and does so in relatively low 
numbers.  Due to high disease burden from T2DM in adults, most literature has been 
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conducted in the adult population.  Type 2 diabetes mellitus is characterized by 
hyperglycemia, insulin resistance (IR), and a relative impairment in insulin secretion42.  
In studying T2DM it is known that an increase in FPG represents IFG while IGT is 
represented by an increased OGTT21.  It is recognized that IFG and IGT have consistently 
predicted an increased risk of diabetes in many populations21.   
It is also recognized that the etiology of T2DM results initially from peripheral IR 
where cells of the liver, fat, and muscles are unable to respond to insulin11.  The reason 
why these tissues are unable to respond to insulin is not entirely understood but it is 
thought that the resistance may be due to changes in receptors, genetic changes, or 
environmental influences42,43.  As Tabak et al. showed in a population of British civil 
servants who were enrolled to the study prior to diabetes diagnosis, those who developed 
T2DM had a marked decrease in insulin sensitivity in the five years prior to diagnosis3.  
As well, β-cell function increased three to four years prior to diagnosis but then decreased 
until diagnosis3.   Thus, β-cell secretion can initially increase to compensate.  This results 
in increased insulin secretion leading to hyperinsulinemia but allows for the stimulus 
needed for insulin resistant cells to take up glucose.  This ability to cope however, is 
eventually overcome resulting in decreased insulin secretion. Eventually the pancreas 
fails to secrete enough insulin, leading to overt T2DM with hyperinsulinemia and 
eventually the necessity of exogenous insulin.  As Tabak et al. note, the above supports a 
multistage model of etiology in diabetes3.  There is a long period of compensation when 
hyperinsulinemia occurs to make up for the insulin resistance without any major changes 
in glucose values.  There is then a “stable adaptation” period when β-cell mass is 
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decreasing in spite of the β-cell adaptation and then a “transient unstable” period with a 
rapid rise in glucose values leading to overt diabetes3.    
 
 
Figure 2: Type 2 Diabetes Pathophysiology (from38) 
 
As Figure 2 indicates there are multiple variables that play a role in the 
development of hyperglycemia and in the ultimate risk for T2DM.  At least in adults, 
certain variables such as overweight and obesity,4,38,44 have been recognized to contribute 
to the development of T2DM.  In obesity, when caloric intake is continuously net 
positive, fat initially accumulates in the subcutaneous tissue.  However, when storage 
capacity is exceeded, storage shifts to other areas including the liver and muscles.  Fat 
accumulation in these tissues results in impaired insulin mediated glucose uptake which 
is thought to be caused by impaired intracellular insulin signaling38.  While it is known 
that there are additional mechanisms at play, as noted by the fact that lean people can also 
be diagnosed with T2DM, obesity is one of the leading risk factors for T2DM due to this 
pathophysiology4,38.   
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In the early 1990s it was recognized that there was an increasing prevalence of 
T2DM in children and adolescents in the United States45.  Since this time increasing 
prevalence of T2DM has also been recognized in studies in Europe, Asia and increasingly 
worldwide45.  The increasing incidence of T2DM has paralleled that of obesity since the 
late 1970s45,46.  While T2DM in adults has been correlated with obesity, it has only more 
recently been recognized that obesity in children, which until recently was rare, has 
similar effects.  To date, the majority of research on T2DM disease has focused on adults, 
since it was considered to be an adult disease for so long.  Thus, T2DM in children has 
not been as extensively studied and much of what is known has been deduced from the 
adult literature.  Yet, the literature that does exist in the pediatric population elucidates a 
pathophysiology that, while it shares many features seen in adults, does show distinct 
differences.  In adults it is recognized that there is a lengthy and prolonged decay in 
glucose tolerance which results in a slow progression from normal glucose tolerance 
(NGT) to IGT21.  Data by Meigs et al. indicate that, in adults, progression from normal to 
diabetes mellitus occurs at a fairly constant rate, at least in most individuals, over the 
course of many years21.  Studies in youth, however, are much less convincing of a slow 
course.  While limited, studies in youth have instead found a rapid deterioration of β-cell 
function during treatment 29,30.  As opposed to adults in whom is has been estimated that 
β-cell function declines at a rate of about 7% per year, β-cell function in youth was found 
to decline at a rate between 15% to 20% per year29,30.  In a study by Katz et al. it was also 
found that adolescents had a worsening in control of their diabetes with increasing insulin 
requirements as soon as 1.5 to 2 years after diagnosis47.  Puberty is also a time of 
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physiologic increase in IR48–50.  Healthy adolescents are able to compensate by increasing 
insulin secretion.  However, in those who are already undergoing β-cell failure, they are 
unable to compensate to overcome the increase in IR23.  While it is unknown, this may be 
a component of why there is a much more fulminant course for adolescents diagnosed 
with T2DM.  This is a diagnosis that poses challenges for both adults and adolescents28,51.  
An adolescent carries the additional burden of adjustments to the changes of puberty with 
this diagnosis.   
 
Epidemiology of type 2 diabetes mellitus in children and adolescents 
The increasing prevalence of T2DM in children and adolescents in the United States was 
initially recognized in the 1990’s.  Prior to this time, reports were rare with the first 
reports occurring in 1979 and 1984 in Native Americans and Canadian First Nation 
People.  A second wave of reports in the mid-1990s appeared and was found to involve 
predominately ethnic minorities45.  Shortly after this time the SEARCH project was 
started.  The SEARCH is an observational, multi-centered study whose primary aim is to 
assess the prevalence and incidence of physician diagnosed diabetes in those less than 20 
years of age.  It was initiated in 2000 and is planned to run through at least 20201,17,52–54.  
Participants were recruited from six recruitment centers around the United States and 
their distribution can be seen in appendix 1.  These locations were selected to provide a 
wide ethnic and socioeconomic sample54.   
Prevalence data was collected in 2001 and 2009 and incidence data has been 
collected annually since 2002.  In analyzing the 2001 and 2009 data it has been found 
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that overall diabetes prevalence increased, including all types of diagnosed diabetes.  
Type 2 diabetes saw an increased prevalence of 30.5% with increases in both sexes, those 
aged 10-14 years, 15-19 years, and among Hispanic and non-Hispanic white and African 
American youth, which authors indicate is similar to findings in other small scale 
studies52.  Type 1 diabetes still represents the vast majority of diabetes diagnoses in 
children and adolescents; however, the increase in prevalence of T2DM is greater than 
that of T1DM (21.1%).  While the numbers here are striking they are likely to be an 
underestimate.  As the authors note, a limitation to the study is that these were all 
physician based diagnoses, which excludes those who are asymptomatic and unaware 
they have the disease17.  Additionally, the authors indicate that older adolescent 
populations are less likely to go to the doctor, making identification difficult and likely 
further underestimating T2DM in this portion of the sample.  
 Another striking finding from SEARCH and others is that T2DM 
disproportionately affects racial and ethnic minorities52,23,55.  SEARCH has found high 
incidence and prevalence rates, especially in minority populations.  Figure 3 shows the 
incidence rates for 2002-2003 for various ethnicities23.  In 2009 prevalence data was 
examined and it was found that the prevalence increased most in Hispanic youth.  African 
American youth had a minor increase as did non-Hispanic white youth.  While the 
prevalence was still overall highest in American Indian youth there was a slight decrease 
in prevalence in this population as well as in Asian/Pacific Islander youth52.  This 
provides evidence that there is a need for early recognition and screening, especially in 
these populations. 
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Figure 3. Incidence of Type 2 Diabetes in Youth of Differing Ethnicities 
 
Screening for prediabetes and diabetes 
While prediabetes is not a diagnosis in and of itself and the ADA cautions that it should 
instead be considered a sign of increased risk of diabetes and cardiovascular disease4, it is 
a condition characterized by mild hyperglycemia.  Currently, in children and adolescents, 
decision to screen for prediabetes is made using a set of criteria based on body mass 
index (BMI) and additional risk factors.  Based on the 2007 Expert Committee 
Recommendations Regarding Prevention, Assessment and Treatment of Child and 
Adolescent Overweight and Obesity, Haemer et al. as the FOCUS on a Fitter Future 
(FFF) group suggested screening guidelines as indicated in Appendix 2.  At the time of 
publication the authors provided a consensus rating of D (Expert opinion) for screening, 
suggesting that early identification may be preventative but that more research was 
needed18. 
The ADA’s position as of 2017 now recommends screening based on weight 
(BMI >85th percentile or >120% of ideal for height), plus the addition of any two of the 
following risk factors:  family history of T2DM in first or second degree relative, 
race/ethnicity (Native American, African American, Latino, Asian American, Pacific 
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Islander), signs of IR or conditions associated with IR (acanthosis nigricans, 
hypertension, dyslipidemia, polycystic ovary syndrome, or small for gestational age birth 
weight), or maternal history of diabetes or gestational diabetes mellitus (GDM) during 
the child’s gestation.  The ADA also recommends screening adolescents every 3 years 
after initiation at 10 years of age or onset of puberty, whichever comes first4.  
Controversy exists about screening in children and there is little known about the 
costs and benefits of screening in children18,56.  As Wu et al. found the cost to screen for 
diabetes was great ($312,000 to $831,000 per case identified) and they emphasize that 
this current standard is not cost effective due to the relatively low number of children 
with diabetes57.  However, this became more cost effective when screening for 
dysglycemia, using prediabetes thresholds, though the cost varied by testing method57.  
The authors indicate that, from a cost perspective, it makes sense to screen for 
dysgylcemia.  While the costs to screen are still quite high, it may ultimately be more cost 
effective than the cost of a lifetime of treatment in those found to have T2DM as the 
burden of complications they may accrue over their life is significant36.  However, this is 
an area where future research is needed. 
 
Prevention and treatment 
To date most efforts at prevention have been placed on lifestyle intervention and 
pharmacotherapy, generally with metformin.  Both interventions have shown positive 
results in many studies examining adults and children15,58,59.  However, with the 
overwhelming evidence that microvascular complications begin much sooner than the 
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diagnosis of T2DM2,7,8,10,24,52,60, it is prudent to question how much sooner treatment 
should begin.     
Therefore, prediabetes, as defined by the ADA in 1997, has been getting much 
more attention.  Since this time the number of individuals with prediabetes has 
skyrocketed with an estimated 85 million adults61 and 4 million adolescents (estimate 
based on NHANES data34 and population data41) being considered prediabetic.  At least 
for adults, it is estimated that those with prediabetes are at significant risk of developing 
diabetes with approximately 70% of those with prediabetes expected to develop diabetes 
within ten years62.  However, to date, very little research has been done on children with 
prediabetes, leaving many questions unanswered about when interventions should begin, 
what the most optimal interventions are, and how to most effectively prevent diabetes in 
this young population.            
 
Existing research 
 
The literature on T2DM can broadly be grouped into two categories: prevention and 
treatment.  Prevention includes studies on prediabetes while treatment includes studies 
examining those with a prior diabetes diagnosis. 
 
Prediabetes and the prevention of type 2 diabetes mellitus 
Much of what is known about the prevention T2DM has come out of a few major studies 
in the adult literature.  Specifically, the Diabetes Prevention Program (DPP) and Diabetes 
Prevention Program Outcomes Study (DPPOS) have been monumental in providing 
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information about prediabetes and the transition to diabetes in adults.  Notably the DPP 
found that lifestyle was more effective than metformin and metformin more effective 
than placebo at preventing diabetes.  Use of metformin resulted in a 31% reduction in the 
incidence of diabetes when compared to placebo and lifestyle intervention showed 
greater reductions with a decreased incidence of diabetes of 58%15.  The DPPOS has 
shown that those who continued metformin during an average of 15 years follow up 
maintained a significant reduction in diabetes, on average 18%, when compared to 
placebo24.  Appendix 3 presents major findings from these studies.   
 A follow up to the DPP, conducted by DeJesus et al. examined the rate of 
progression to diabetes at one year and five years among a sample of prediabetic adults63.  
Nearly 11,000 patients with prediabetes were followed for progression to diabetes.  
Participants were primarily Caucasian (96.4%), overweight or obese (83.5%) and under 
the age of 65 (~59%).  Participants were stratified based on entry fasting glucose level of 
101-109 mg/dL (68.2%), 110-119 mg/dl (25.8%) or ≥ 120 mg/dL (6.0%).  It was found 
that at one year 3.7% had progressed to diabetes while by five years 17.1% had 
progressed to diabetes.  Uniquely, it was found that risk of progression did not vary 
linearly with baseline glucose level.  Instead the risk of developing diabetes appeared to 
be lower in those who had a baseline glucose of 100-110 mg/dL while the risk increased 
substantially in those with a baseline glucose greater than 111 mg/dL.  Via modeling with 
population attributable risk (PAR) statistics it was concluded that those with a baseline 
glucose of 110-119 mg/dL, who were adherent to intervention and could reduce their 
glucose levels, would have a greater risk reduction than those with a baseline glucose of 
 20 
120 mg/dL or greater.  This makes the argument that either more screening needs to be 
done or levels need to be lower in order to identify those individuals who are most likely 
to benefit from early treatment.  Several independent risk factors for progression were 
also identified with age and being overweight predicting five year progression to 
diabetes.  Being of Asian or Hispanic background were also found to be independent risk 
factors for progression.  This allows for further information on who to select to screen for 
prediabetes, allowing for early behavior modification to decrease risk of progression. 
 In another study of prediabetic adults, Malin and Kirwan64 examined the effects 
of 12 weeks of aerobic activity on the subtypes of IFG, IGT or combined glucose 
intolerance (CGI).  It was found that exercise reduced body fat mass and total fat 
similarly across groups (p<0.001), yet those in the CGI group maintained more visceral 
fat than the NGT and IGT groups (p≤0.05).  Exercise improved glucose tolerance by 
lowering FPG in those with IFG, CGI and T2DM by 8-16% when compared to NGT and 
IGT (p<0.001).  Insulin sensitivity was found to increase in all groups after exercise 
training (p<0.05). The effects, however varied with prediabetes subtype.  Reversion to 
normoglycemia was more likely in those with IFG compared to those with CGI with a 
70% versus 55% reversion respectively.  This suggests that, at least in adults, in those 
with more severe forms of prediabetes regression is less likely despite interventions.  The 
authors concluded that the subtypes are unique and emphasize the need for further 
evaluation64. 
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Lifestyle interventions in prediabetic youth 
The literature studying prediabetes in children and adolescents is limited.  To date, only 
one study has directly examined lifestyle interventions in prediabetic adolescents.  This 
study, by Savoye et al. was conducted using the Yale Bright Bodies (BB) protocol, which 
is a family based lifestyle intervention that is tailored for inner-city minority youth and 
their families65.  This program has been shown in other trials to be an effective means of 
weight loss, decreasing BMI, improving insulin sensitivity and glucose tolerance in 
adolescents66–68.  These studies have shown maintenance of these effects to be sustainable 
for up to 12 months.  In the prediabetes study65, the BB program examined a group of 
obese adolescents aged 10-16 years who were prediabetic with an OGTT between 130-
199 mg/dL.  Participants were randomized to either BB program or standard clinical care 
(CC).   
Of 577 children screened, 145 (25%) met inclusion criteria.  Of these 75 were 
randomized (51.7%).  Thirty-one participants (81.6%) completed the BB arm and 27 
(73%) completed the CC arm of the study.  Of those enrolled, the BB group was 35.5% 
non-hispanic white, 41.9% Hispanic, 22.6% black and 0% other.  The CC group was 
29.6% non-hispanic white, 37% Hispanic, 25.9% black and 7.4 % other.  Both groups 
averaged 12.9 years of age.  The groups were 32.3% (BB) and 33.3% (CC) male.  At 
randomization there were no significant differences in demographic, glucose or insulin 
metabolism, anthropometrics or cardiovascular data between groups.  It was found that 
there were significant reductions in OGTT in both BB (-27.2 mg/dL) and CC (-10.1 
mg/dL) groups, but the improvements were significantly greater in the BB group 
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compared to the CC group (p=0.005).  Significantly greater improvements were also seen 
in the BB group for fasting plasma insulin (p=0.026), two hour plasma insulin, (p<0.001) 
homeostasis model assessment of insulin resistance (HOMA-IR) (p=0.003) and whole 
body insulin sensitivity index (WBISI) (p=0.02).  Individual means can be seen in Table 
3.  Throughout the study none of the participants developed diabetes.  However, 19 of the 
31 (61%) BB subjects who had an OGTT ≥130 mg/dL at baseline reverted to < 130 at six 
months.  This was only the case for 6 of 21 (22%) of the CC participants.  Additionally, 
42% of the BB subjects had two hour OGTT ≤ 120 mg/dL while only 7% of the CC 
group fell under this (p=0.003).   
Table 3. Significant Characteristics of BB vs CC Group in the Bright Bodies Study 
Characteristic/Test BB CC 
Weight (kg) 0.6 3.7 
BMI -0.37 0.67 
BMI z-score -0.05 0.04 
% fat -3.3 0.4 
Fat mass (kg) -2.7 2.3 
Fasting plasma insulin (µIU/mL) -4.9 5.2 
2 hour insulin (µIU/mL) -108.6 -15.7 
HOMA-IR -1.2 1.4 
WBISI 0.41 -0.01 
 
The BB group also had statistically significant changes in weight, BMI, BMI z score, 
percent body fat and fat mass when compared to the CC group.     
A major strength of this study was that it showed that lifestyle intervention in 
adolescents with prediabetes has the ability to, in many youth, reverse glucose 
impairments and is more effective than waiting until the development of overt T2DM.  
This study was limited in sample size and duration.  Another limitation for the BB group 
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was the major commitment that required not only by the participants but also all care 
givers, family members and community members which also limits the studies 
generalizability.  However, being only six months in length, the authors note may 
actually be a strength as results were seen so quickly.  Another limitation of the study is 
that there was no follow up after the end of the intervention to see if the effects were 
durable.  The authors also note that the success of the lifestyle intervention program 
suggests the importance of intervening at this stage and not waiting until the development 
of T2DM in this population65. 
 
Exercise literature in youth  
As the BB and DPP studies have indicated, exercise is an integral part of therapy for 
those with prediabetes.  However, the question remains as to what kind of physical 
activity is most effective in the youth population.  A large hurdle is simply getting kids 
moving.  It is known that most youth are remarkably sedentary19,69, but this is particularly 
true for those with obesity and diabetes.  The TODAY study is to date the largest and 
most well characterized sample of American youth with recent onset T2DM28 and has 
examined lifestyle and pharmacotherapy.  In a follow up to the initial TODAY study it 
was found that when compared to an NHANES population of obese adolescents, the 
youth in the TODAY study were significantly more sedentary than comparable youth in 
NHANES70 (p<0.001).  The groups were similar, with the TODAY population being 
56% male and NHANES sample 51.5% male.  Both studies were composed of ethnically 
diverse samples: non-Hispanic white (TODAY 17.8%; NHANES 62.4%), Hispanic 
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(45%; 15.5%), non-Hispanic black (29.8%; 14.6%) and other (7.5% NHANES).  What is 
most remarkable, however, is the overall degree of how sedentary these youths were.  In 
this study the 10-14-year-old girls averaged less than 30 minutes of activity a day.  This 
number decreased to less than 15 minutes per day for 15-18-year-old girls.  While boys 
were more active, particularly those in the 10-14-year age range, the TODAY cohort was 
significantly less active than NHANES (p<0.05).  Additionally, activity levels dropped to 
under 30 minutes for boys 15-18 years old.  Sedentary behavior for the entire cohort 
exceeded 400 minutes per day70.     
While most studies being conducted involving exercise in youth are focused on 
obesity and weight loss, there are several that include components of glucose metabolism 
and prediabetes in their studies.  A review article by Kim and Park examined available 
evidence for the role of exercise training without calorie restriction for reducing IR in 
children and adolescents71.  They examined the effects of either aerobic exercise or 
resistance (or combined) exercise on IR.  From the aerobic training studies, the authors 
concluded that there is evidence that regular aerobic exercise, even without weight loss or 
calorie restriction, is beneficial in improving IR in overweight and obese youth.  
Participating in daily resistance type training also showed improved IR leading the 
authors to conclude that both aerobic and resistance exercises alone, without dietary 
restriction, resulted in significant improvement in insulin sensitivity in overweight and 
obese children and adolescents.  The authors do also note that more studies are needed to 
examine what the optimal dose of exercise is as well as what the most efficacious and 
meaningful modes are in youth71.  
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Davies et al. conducted a study examining the effects of aerobic and strength 
training in overweight Latina adolescents72.  This was a pilot study and participants were 
randomized to one of four interventions; control (C), nutrition (N), nutrition plus strength 
training (N+ST) or nutrition plus combined aerobic and strength training (N+CAST) with 
descriptions of each intervention in Table 5.  The trial was conducted over 16 weeks and 
included Latina adolescents with a mean age of 15.2 and Tanner stage of 4 or 5.  There 
were 50 subjects that qualified and 41 (82%) completed the study with percent 
completers in Table 4. 
Table 4. Davies et al. Interventions 
Group Intervention Completers 
N; % 
C Control group; no intervention 
Pre-testing and post-testing only 
7 
17 
N Culturally tailored dietary intervention with one 90-minute 
session per week 
10 
24.4 
N+ST Same nutrition education as N group 
Two days per week of approximately 60 minutes strength 
training 
9 
22 
N+CAST Same nutrition as N group 
Two days per week of approximately 60 minutes combined 
aerobic and strength training 
15 
36.6 
 
There were no differences found between the intervention groups at baseline (all 
p>0.21).  Significant changes across groups were found for body weight (p=0.004), BMI 
(p=0.001), BMI z score (0.003), total fat mass (p=0.045) and fasting glucose (p=0.047).  
Additional data on mean changes can be found in Table 5.  There were no significant 
differences between groups in two hour OGTT, fasting insulin, or two hour insulin.    
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Table 5: Significant Characteristics Between Interventions 
Characteristic/Test C N N+ST N+CAST 
Weight -0.3 0.3 2.4 -0.8 
BMI -0.5 0.3 1.1 -0.5 
BMI z-score 0.00 0.02 0.08 -0.05 
Fat mass (kg) 0.4 -0.1 0.6 -1.4 
Fasting glucose (mg/dL) -3.9 2.5 -3.6 -4.3 
 
It was concluded that while there were no significant improvements in metabolic 
parameters, there were significant improvements in adiposity, particularly in the 
combined group.  The authors note that while this improvement in adiposity is 
encouraging, the lack of changes in metabolic parameters warrants further study72. 
Another study by de Mello et al. examined long-term effects of aerobic plus 
resistance training in obese adolescents73.  In this study participants were divided into 
aerobic training (AT) or aerobic training plus resistance training (AT+RT) groups.  The 
study enrolled 43 participants, but only 30 (70%) completed 75% (the minimum to be 
considered completers) of the training.  Of those that dropped out, seven were in the AT 
group and six in the AT+RT group.  Testing occurred at baseline, six months and 12 
months.  Results found that AT+RT was more effective than AT only at controlling the 
features of metabolic syndrome including BMI, fat mass (%, kg, and lean mass), and 
waist circumference at one year (all p≤0.05).  The AT+RT group also had a statistically 
significant change in glucose (p≤0.05) and total cholesterol at one year (p≤0.05).  Mean 
changes of data that reached a significant of p≤0.05, at one year, are presented in Table 6. 
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Table 6: Significant Variable Changes at 1 Year of Study 
Characteristic/Test AT AT+RT 
Weight -7.91 -15.45 
BMI -2.62 -5.54 
Fat mass (%) -2.87 -11.42 
Fat mass (kg) -5.67 -17.34 
Lean mass (kg) -2.29 2.31 
Glucose (mg/dL) 1.16 -6.38 
Total cholesterol (mg/dL) 4.53 -19.84 
 
The authors concluded that while AT provided improvements in some clinical 
parameters, AT+RT was more effective and could provide a new therapeutic target for 
obese adolescents73. 
As a whole, these results, all indicate the benefit of exercise.  The benefits of 
combined aerobic and strength training also appear to be promising.  Thus, activities that 
combine aerobic and strength training, such as CrossFit™ or similar high-intensity 
functional training (HIFT) workouts, should be examined.  CrossFit™, as an exercise 
modality, was officially founded by Greg Glassman in 200074, but was the result of 
Glassman’s years of coaching and his own training.  Glassman has described fitness as an 
increased work capacity across broad time and modal domains75.  CrossFit™ itself is 
described by constantly varied functional movements performed at high intensity75.  The 
modality of CrossFit™ includes functional movements, and these movements reflect the 
best aspects of gymnastics, weightlifting, running, rowing and more75.  The overall aim 
of CrossFit™ is to forge a broad, general and inclusive fitness supported by measurable, 
observable and repeatable results75.  One of the benefits of the program is that it is 
universally scalable, allowing for participation from all levels of fitness.  While the 
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literature studying CrossFit™ itself is sparse, what is available does provide evidence for 
benefits such as increasing aerobic capacity and improving body composition76,77.  An 
article by Fealty et al. also describes the benefits of CrossFit™ in adults with T2DM for 
increasing β-cell function and insulin sensitivity78.        
Another strong benefit for CrossFit™ is the community aspect that it is associated 
with.  As found in a pilot study by Kin et al. called “Beating Diabetes Together” 
participants routinely mentioned the importance of the group atmosphere on their 
participation51.  Participants noted how the relationships they formed in the program were 
important for their overall health.  Another key to getting adolescents to be physically 
active is motivation19,72.  The positive benefits of goal setting, as demonstrated by Love-
Osborne et al. and as emphasized by the CrossFit™ environment may be what is needed 
to get the “buy in” for adolescent involvement55.         
 
Metformin in youth 
Metformin has been a mainstay for the treatment of T2DM in adults where it has been 
shown to increase insulin sensitivity and inhibit gluconeogenesis and lipolysis79.  In the 
U.S. metformin has been in use since 199580.  However, its use in youth has not been 
readily studied.  Metformin became FDA approved for use in children over the age of 10 
in 2000 for its use in T2DM81.  Most studies to date examining metformin in youth are 
small samples of short duration.  Yet, more and more studies are being done examining 
the effects of metformin in youth and most are finding good safety profiles.  In a 2015 
review of literature by Hostalek et al. part of the review included pediatric literature on 
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the use of metformin in prediabetic populations58.  Appendix 4 reviews the findings from 
the seven papers identified in the review33,82–87 plus two additional papers examining the 
use of metformin on youth with insulin resistance55,88.  The safety profiles were noted to 
be good in most of the studies, many of them noted side effects, with most studies 
reporting approximately 30% of the metformin groups experiencing side 
effects23,33,55,83,84.  The placebo groups noted similar side effects ranging from 
approximately 7%83 of the sample to 22%88.  These side effects were generally 
gastrointestinal including nausea, diarrhea and abdominal discomfort.  Though there has 
been an increased use of metformin in the T2DM and obese youth populations data on 
efficacy, safety and pharmacokinetics data is limited.  All studies to date are of short 
duration and dosing has been based off of tolerability and what has been found to be 
effective in adults.  Thus, in 2014 the METFORMIN study, a multicenter randomized 
double blind placebo controlled prospective trial was initiated to examine the efficacy, 
safety, tolerability and pharmacokinetics of metformin, in combination with lifestyle 
interventions, in obese adolescents89.  At the time of this writing results are still pending 
but the authors are hoping to be able to provide evidence on efficacy of metformin as 
well as safety, tolerability and to describe the pharmacokinetics in obese adolescents89.   
 
Type 2 diabetes mellitus and its treatment 
The Look AHEAD (Action in Health in Diabetes) study has been instrumental in 
providing information about the consequences of T2DM.  Major results of this study can 
be found in Appendix 3.  While the primary outcome examining cardiovascular mortality 
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showed no significant differences between groups (p=0.51), this study did show benefits 
in decreased weight, improved A1C and less insulin requirements.  Those in the 
intervention group were also more likely to have a partial remission of their diabetes 
during the initial active period then were those in the control group44.  
The initial TODAY study28, as briefly mentioned earlier, screened 1211 
participants, of which 927 (76.5%) entered the run in phase and 699 (75.4%) were 
randomized.  With a mean duration of diabetes of 7.8 months participants were 
randomized to one of three groups; metformin alone (M), metformin plus rosiglitazone 
(MR), or metformin and intensive lifestyle intervention (ML).  The primary outcome was 
loss of glycemic control indicated with an A1C of 8% or greater for six months or insulin 
requirement.  It was found that 319 (45.6%) met the primary outcome and that the 
median time to failure was 11.5 months.  The MR group was superior to M group with 
failure rates of 38.6% and 57.1% respectively.  The ML group had intermediate failure 
rate of 46.6%.  BMI over time differed significantly according to treatment (p<0.001) 
with the MR having the greatest increase in weight and the ML having the greatest 
decrease.  The authors concluded that in youth with T2DM, monotherapy is not sufficient 
with many youth requiring dual pharmacotherapy.  This is clinically important as 
currently only metformin is FDA approved for use in pediatrics, specifically for those 
with T2DM, not prediabetes.  Use of any other agents, or use of agents in prediabetes, 
need to be considered on a case by case basis for off label use.  However, it is notable 
that the ML group had the greatest decrease in weight.   
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  In a TODAY follow up90 it was found that after 24 months of treatment, 
metabolic syndrome remained prevalent (75.8%) in the TODAY population with no 
overall changes in prevalence or incidence (p=0.89).  This leads to the conclusion that 
these individuals need to be monitored for cardiovascular disease risk as the relationship 
between T2DM and cardiovascular risks is currently unknown.  However, since these 
youths have such an extended duration of disease, the risks are likely to be increased and 
these individuals need close monitoring.  
The evidence on therapy in adolescents with prediabetes is promising.  However, 
there is still very little literature examining prediabetic youth which makes decision 
making for clinicians very difficult.  While Bailey et al. examined the uptake of 
guidelines for obesity37, the principles in prediabetes are similar and one can imagine the 
struggle a primary care provider may encounter in how to treat an adolescent meeting the 
criteria for prediabetes.  As noted by Hanna et al, to date no head to head studies 
examining physical activity and metformin exist in pediatric pouplations19.   
This leaves many unanswered questions.  Questions such as:  how many 
adolescents diagnosed with prediabetes go on to become diabetic and in what time frame 
does that occur?  In those with prediabetes what is the most effective way to restore 
normoglycemia?   Through what interventions can normoglycemia be achieved and can 
the effect be maintained long term?  Are the current guidelines adequate for identifying at 
risk youth?  Are the appropriate metrics being used?  The following study proposal will 
attempt to answer many of these questions.  
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METHODS 
Study design 
The study will be a randomized controlled study.  This pilot study will be designed to 
determine rates of treatment failure by progression to diabetes between two groups: one 
intervention with metformin and standard of care and a second with CrossFit™ as an 
intensive lifestyle modification along with all other standard of care recommendations. 
 
Study population and sampling 
Participants will be recruited from local pediatricians and pediatric endocrinologists in 
Boston and the greater Boston area.  Participants will be referred based on having risk 
factors for T2DM, including criteria such as obesity, hyperlipidemia, insulin resistance, 
family history or ethnicity.  They will then be enrolled based on meeting the inclusion 
and exclusion criteria as presented in Table 7.  Recruitment will occur over a six month 
period, after which participants will be randomized to one of the two treatment groups.  
Table 7. Inclusion and Exclusion Criteria for Proposed Study 
Inclusion Criteria Exclusion Criteria 
-Age 10 -17 
-BMI > 85th percentile 
-Prediabetes as defined by the ADA: 
-FPG: 100 – 125 mg/dL 
-OGTT: 140 – 199 mg/dL 
-Hemoglobin A1C 5.7-6.4% 
-Anyone with a diagnosis of diabetes 
-Individuals with medical conditions that 
affect glucose metabolism  
-Individuals taking any medications 
known to alter glucose metabolism 
-Individuals whose families plan on 
moving in the next two years 
-Pregnancy 
 
The primary outcome is treatment failure via progression to diabetes as measured by 
either FPG, OGTT, or A1C above threshold levels over consecutive readings according 
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to ADA standards.  A sample size of 150 participants will be recruited based on a 
predicted treatment failure demonstrated by progression to diabetes of 5% with lifestyle 
intervention and 20% with metformin, an alpha of 0.05 and a power of 80%91.  Due to a 
likely high dropout rate, participants will be over sampled with a goal of 100 participants 
per treatment arm.  A secondary outcome is restoration of normoglycemia as measured 
by the regression of FPG, OGTT, or A1C to normal values.  Tertiary outcomes will 
examine other laboratories related to metabolic syndrome including fasting insulin, lipids 
and, weight.  A p-value of 0.05 will be used for all analysis. 
 
Treatment (or intervention) 
Participants will be randomized equally to one of two groups.  One group will receive 
standard of care plus metformin daily.  The other will receive standard of care plus 
intensive lifestyle intervention using a CrossFit™ program.   
 
Standard of care 
Both groups will be treated with the standard of care and will continue to be followed by 
their primary care provider annually.  They should receive diet and exercise 
recommendations provided by registered dieticians and their primary care providers.  
Nutrition counseling should include avoiding juice and sugary beverages, drinking low-
fat milk instead of whole milk, and bringing lunches to school instead of buying them.  
Standard exercise counseling should focus on encouraging activities that are enjoyed with 
the goal of regular engagement in physical activity and decreased sedentary activities.  
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Goals for exercise and nutrition should be discussed with both the participant and a care 
giver to make sure that the plan is realistic and acceptable to the adolescent and the parent 
and family.  
 
Lifestyle intervention with crossfit 
Participants who are randomized to the lifestyle intervention group will begin training 
twice per week at a designated CrossFit™ “box” (the location of the gym where 
participants will be trained and workout).  After two months an additional day of activity 
per week will be added increasing planned activity per week at the box to 180 minutes.  
The box will be located either near the study center or in a location where there are 
clusters of participants homes to make it easy for participants to get there.  Trainers will 
be staff at the local box and will be certified as a CrossFit kids coach.  It is expected that 
there will be a 1:6 ratio of coaches to participants.  Study staff will drop into the box once 
per month to observe participants, their training, and to assess program compliance.  
Participants will be split up based on age with a class for those 10-13 years old and those 
14 years old and over.  Each class is expected to last 60 minutes in duration.  A typically 
class will include a 10-15 minute warm up of light activity, a game, and stretching.  This 
will be followed by approximately 15-20 minutes for skills training.  Skills training will 
vary based on the day but may include items such as: pull ups, push ups, box jumps, 
barbell, kettlebell or dumbbell work.  The next 15-20 minutes will be used for an aerobic 
based workout with incorporated strength components.  An example may include doing 
as many rounds as possible (AMRAP) in 10 minutes of a certain number of each of the 
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following: pull ups, lunges and box jumps.  The remainder of the class will be used to 
play a game, cool down and discuss things such as how the work out went, nutrition or 
what kinds of additional activities kids are doing outside of the box.  The emphasis of any 
discussion during this time period will be on healthy living, goal setting, and achieving 
good balance in regards to nutrition as well school and other aspects of life. 
  Classes for the participants will be free of charge and the instruction time will be 
donated by staff members of the box involved.  To encourage the extension of lifestyle 
intervention into the home, parents or guardians of participants will be able to sign up for 
a membership at a deeply discounted price while their child participates in the program.    
 
Metformin intervention group 
Participants randomized to this group will begin with a loading period for metformin by 
initially taking 500 mg daily for two weeks.  For the next two weeks they will add 
another 500 mg in the evening.  Finally, on week five they will add another 500 mg to the 
am dose for a total of 1500 mg daily.  This is done in an attempt to avoid the known 
gastrointestinal effects.  If participants are unable to tolerate side effects they will remain 
at last dose without effects for a longer duration before again advancing them.  The goal 
will be to have all participants taking 1500 mg metformin daily.  Pill counts will be 
obtained at each clinic visit to determine treatment adherence.  All metformin will be 
provided to participants free of charge. 
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 In receiving standard of care, the metformin group will also be encouraged to 
increase their activity levels and decrease sedentary behaviors.  They will be counseled 
on good nutrition by dietitians and their primary care providers   
 
Study variables and measures 
Participants will be followed at the study center once every two months for the active part 
of the study.  They will then be followed every six months post-intervention and for the 
reminder of the study duration which is until participants are 22 or are lost to follow up.   
 
Demographics 
Demographics will be collected from participants at enrollment.  This will include age, 
gender, race/ethnicity, and insurance information.  Age and type of insurance will be 
verified at each future visit.   
 
Anthropometrics  
Height will be measured in bare feet to the nearest millimeter with a wall stadiometer.  
Weight will be measured with participants in bare feet, undergarments and a light gown 
and will be recorded to the nearest 0.1 kg.  BMI will be calculated based on height and 
weight.  Blood pressure will be measured in each arm with a calibrated automatic 
sphygmomanometer after participants have been quietly sitting for five minutes.  If large 
differences exist between arms participants will be asked to sit quietly for another five 
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minutes before repeating the readings.  Readings will then be averaged.  Height, weight, 
BMI and blood pressure will be collected at each visit.   
 
Oral glucose tolerance test (ogtt) 
Oral glucose tolerance will be collected at baseline, one year and two years.  OGTT will 
be administered first thing in the morning after an overnight fast of 10 hours.  Parents and 
participants will be instructed on how to fast the night before the test.  Participants will be 
asked to consume a low carbohydrate diet and to refrain from strenuous exercise the day 
before. Participants will have an intravenous catheter placed for collection of blood 
samples.  After 15 to 20 minutes of post IV placement rest, baseline samples will be 
collected including FPG, fasting insulin, lipids, ALT, and A1C.  Participants will then be 
provided a flavored oral glucose solution at 1.75 g/kg body weight with a maximum dose 
of 75 mg.  Blood samples will then be collected in 30 minute increments for blood 
glucose and insulin, for a total duration of two hours.   
 
Laboratories to be collected every visit 
Every two months when participants return to clinic for follow up they will repeat a FPG, 
fasting insulin, and A1C level.  HOMA-IR will be calculated from FPG and fasting 
insulin values, where HOMA-IR = insulin (µIU/mL) x glucose (mg/dL).  
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Other laboratory outcomes 
Additional blood work will be obtained biannually to evaluate total cholesterol, high 
density lipoproteins (HDL), low density lipoproteins (LDL), and triglycerides. 
 
Recruitment 
Participants will be recruited from local pediatric and pediatric endocrinology clinics in 
Boston and the greater Boston area.  All providers in the local clinics will be notified of 
the trial and of openings for enrollment.  Participants should be referred for screening if 
they have a BMI in the 85th percentile or greater or other T2DM risk factors.  At initial 
screening participants will have completed a 10 hour fast to be evaluated for FPG, fasting 
insulin and A1C.  Participants will be screened for interest in enrollment.  If found to be 
prediabetic based on ADA criteria for prediabetes and other inclusion criteria participants 
will be asked to consent for enrollment in study.  If FPG is found to be elevated and not 
A1C, participants will need a second elevated FPG on another day to be enrolled in the 
study.  
 
Data collection 
As participants are enrolled they will be coded and data will be entered based on their 
code.  All data will be entered into a secured server for each clinical site.  Data will be 
merged routinely for analysis and will be stored in a secured cloud. 
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Data analysis 
The primary outcome will be treatment failure via progression to diabetes and will be 
reported as either diabetes or no diabetes.  This will be reported by mean number and 
standard deviation of those who have failed treatment and progressed to diabetes and will 
be compared with a chi-square test.  Mean and standard deviation will be reported for all 
anthropometric data (age, weight, height, BMI, blood pressures and percent body fat), 
participant age and all laboratory variables (FPG, fasting insulin, lipids (total cholesterol, 
HDL, LDL and triglycerides), ALT, A1C, and glucose and insulin at 30, 60, 90 and 120 
minutes for OGTT).  Other demographic data (male/female, race/ethnicity, and insurance 
information) will be reported with percentages.  Chi-square tests will be used to 
determine differences in percentages of gender, race/ethnicity, BMI and insurance 
information.  Within group and between group differences will be analyzed with t-tests at 
baseline, six months, one year, and two years.   
 
Timeline and resources 
Enrollment will be open for a duration of six months prior to the beginning of the 
intervention.  At the end of this time all enrollees will be randomized to intervention.  
The intervention program is expected to last two years.  After that participants will then 
be followed every six months until they reach the age of 22 years or until they are lost to 
follow up.  To make follow up manageable as participants age and relocate for school and 
jobs they will be able to go to a lab of their choice for lab work which will be done once 
every six months.   
 40 
Various staff will be needed at the clinical site.  A primary investigator and a 
study coordinator will be housed in the recruitment center.  Laboratory work will be 
performed by trained laboratory staff.  Specific staff will be used during times when 
numerous participants will be arriving for sampling in order to decrease overall burden 
on staff.  A pharmacist will be recruited for assistance with disbursement of metformin, 
managing patients who should have side effects and performing pill counts at visits.  
Staff from the boxes will provide training for the CrossFit™ groups.  A dietitian will 
provide nutrition advice for the participants and parents.  Participants will continue to be 
followed by their own physicians as well as the study staff.  A statistician will be 
recruited to complete all statistical analysis, monitor all data and to check for outcomes 
that would require modification to or dictate stopping of the study. 
 
Institutional Review Board 
The protocol will be reviewed and approved by the institutional review boards at the 
research institution.  The IRB will require full board review due to the enrollment of 
minors, a protected population, in the program.  An active IRB will be maintained for the 
duration of the study.  Written consent for participation will be provided by a parent or 
guardian and written assent will be obtained from each participant.   
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CONCLUSION 
Discussion 
To our knowledge this will be the first study to run a head to head comparison of 
intensive lifestyle intervention versus metformin for the prevention of diabetes in 
prediabetic youth.  This will also be the first study to use the CrossFit™ methodology as 
an intervention for prediabetic adolescents.  This study will be the first to provide 
information about the long term ability of the interventions to prevent progression to 
diabetes in prediabetic adolescents.  
 A major strength of this study is the duration, both of intervention and of follow 
up.  While most lifestyle interventions studies range in duration from six months to one 
year, the proposed duration of two years will allow for two major advantages over prior 
studies.  First, it will allow for a long term study of metformin use in adolescents.  This 
will allow for the ability to determine if there are longer term consequences to the use of 
metformin, as most prior studies have only examined short term data.  The second major 
advantage is the long term lifestyle intervention.  This provides the ability to determine 
what happens to the prediabetic adolescent over the course of puberty and what the 
outcome is after an extended duration of intensive physical activity, notably with HIFT.  
Additionally, the study design plans for long term follow up of the participants.  This is 
important as it will allow for the cohort to be followed into adulthood to determine if 
there are lasting effects from the interventions.  Additionally, long duration intervention 
allows for a unique opportunity to examine if, after this extended duration and with the 
anticipated outcomes, this may be enough for youth to develop habits that will persist 
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into adulthood92.  The sampling method is also likely to serve as a strength as it is 
intended to sample a diverse population of participants from a diverse city and its 
surrounding areas.  This should allow for generalizable results that can be translated to 
the United States population and beyond. 
 A major limitation of this study is the relatively small sample size.  This however, 
is still larger than most samples in the current literature, so this may end up being 
advantageous and allow for more generalizable results.  The sampling method may also 
serve as a limitation, as this may or may not allow for a diverse sample of participants, 
since there will not be stratification for race/ethnicity.  The need to over sample due to 
the likely high dropout rate is also a limitation that needs to be considered.  The use of 
CrossFit™ as an intervention may also be an advantage and a limitation.  It is a limitation 
as it is an expensive training modality which can be a financial limitation for a large 
number of people, especially since many of the youth afflicted with T2DM come from 
low socioeconomic families.  However, having these youth train in this capacity could 
also be seen as an advantage, as once they learn the basic skills, CrossFit™ is a 
methodology that can be done nearly anywhere and with very limited resources.  A 
former participant could easily take this back to their community and with little space and 
resources have a very large impact on their community as a whole.   
 
Summary 
There is currently a gap in knowledge about the prevention of diabetes in prediabetic 
youth.  Much of what is known has either been deduced from studies on adults or small 
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scale studies examining those who already have diabetes.  Yet, it is known that for the 
most part, T2DM can at least be delayed, if not prevented.  While the steps needed to 
prevent progression appears to be clear, what is still unclear is how much can be done 
about it once the adolescent is prediabetic.  While there is evidence suggesting that 
adolescents can improve their blood glucose homeostasis through lifestyle intervention, 
there are no long term studies to identify if this is a durable change or if it is transient.   
 Studies on lifestyle intervention in adults have shown that there is benefit to 
weight loss and physical activity in reversing prediabetes15,24,63,64.  Metformin also has 
been show to improve indices of glycemia in adults15,24.  However, the pathophysiology 
in children and adolescents does not appear to be identical to that in adults29,30.  This may 
mean that for interventions to be successful, especially for an extended duration, the 
condition may need to be recognized much sooner and interventions started well before 
overt diabetes.  Thus, there is a need for adequate screening and monitoring in order to 
allow for intervention during the earliest stages possible.  
 The literature that is available examining adolescents mainly focuses on either 
intensive lifestyle intervention or the use of metformin.  In studies examining lifestyle 
intervention most studies have participants engaging in aerobic activity, however there 
are others that have examined strength training or a combination of aerobic and strength 
training.  The BB study, while short in duration, did find differences in the intensive 
lifestyle intervention vs standard care, with more participants in the intervention reverting 
to an OGTT of less than 130 than in the standard of care group (61% vs. 22% 
respectively).  In studies that have examined the benefits of exercise most, regardless of 
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methodology, have found that those who participate in activities have benefits in glucose 
regulation or insulin sensitivity46,71,93.  Interestingly, Davies et al. found that those who 
participated in a combination of aerobic and strength training showed greater decreases in 
fat mass and fasting glucose then in those who participated in either exercise alone72.  
Thus it appears that one of the most important interventions is getting adolescents 
moving.  This is critical since studies have shown that adolescents in general, but 
especially those that are obese or have T2DM, are incredibly sedentary69,70.  
 The studies that have examined the use of metformin in children and adolescents 
have also shown benefits in glucose regulation or insulin sensitivity as the Hostalk et al. 
review paper indicated58.  However, no studies have directly compared this to lifestyle 
intervention as has been done in adults in the DPP.  This makes it very difficult to know 
which intervention provides the best protection against the future development of 
diabetes.  Additionally, metformin is not currently approved for prediabetes in children 
and adolescents and thus clinicians have no guidance on its use in this population. 
 Thus, in conclusion, the proposed project will allow for the exploration of 
preventative practices of diabetes in prediabetic youth.  This is significant as there is 
currently very little literature examining prediabetic youth and an absolute lack of 
literature comparing intensive lifestyle intervention to the use of metformin in this 
population.  Therefore, this study will address not only a gap in the literature, it will also 
address the prevention of a disease that affects millions of youth and adults in the United 
States, as well as many more globally.      
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Clinical and/or public health significance 
The potential clinical implications for this study are monumental.  This study will allow 
for a greater understanding about the preventability of T2DM in prediabetic adolescents.  
It will also aid in understanding the long term risks and benefits of early intensive 
lifestyle intervention using CrossFit™ as well as metformin use.  Finally, while the costs 
associated with a study such as this are great, the results will provide information on how 
to most effectively manage prediabetes and aid in addressing the public health issues 
associated with the extreme costs of treating diabetes. 
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APPENDIX 1 
 
Distribution of SEARCH Study Locations 
Site 
Characteristics 
 
State 
 
Additional Info: 
Geographic 
Based: 
Ohio Eight counties including Cincinnati 
Colorado Entire state plus management of American 
Indian reservation based populations in Arizona 
and New Mexico 
Washington Five counties around Seattle 
South Carolina Entire State 
Health Plan 
Based: 
California Enrollees of one plan from 7 counties 
Hawaii Enrollees in various health plans, which 
incorporate ~95% of the population 
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APPENDIX 2 
Type 2 Diabetes Screening in Asymptomatic Pediatric Patients as Recommended by the 
FOCUS on a Fitter Future4,18 
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APPENDIX 2.  
Type 2 Diabetes Screening in Asymptomatic Pediatric Patients as Recommended by the 
FOCUS on a Fitter Future4,18 
BMI CRITERIA For Screening: 
1. All children or adolescents who are severely obese (BMI >99th percentile) 
2. Children or adolescents at the earlier age of 10 or onset of puberty with: 
a) Obesity (BMI >95th percentile) 
b) Overweight (BMI 85th - < 95th percentile) with one or more additional risk factors 
Risk Factors 
x Family history of T2DM in first or second-degree relative 
x High-risk race/ethnicity (African American, Latino, Native American, Asian 
American, or Pacific Islander) 
x Signs of insulin resistance or conditions associated with insulin resistance: 
o Hypertension (systolic or diastolic blood pressure > 95th percentile for age 
and sex) 
o Dyslipidemia 
o Maternal history of diabetes or gestational diabetes during the child’s 
gestation, low or high birth weight 
o Patients prescribed second-generation antipsychotics 
Age at Initial Testing 
x 10 years or at onset of puberty if puberty occurs at a younger age 
x Under age 10, or prepubertal if child has BMI > 99th percentile or has one or more 
additional risk factor 
Retesting 
x Biannually if normal, more frequently for abnormal values, rapid increases in weight, 
development of other comorbidities (hypertension or dyslipidemia), and/or onset of 
puberty 
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APPENDIX 3 
Preventative and Therapeutic Effects in Prediabetes and T2DM 
Study 
 
Study  
Type 
Treatment (n); 
study duration 
Major Criteria  
for Enrollment: 
Outcomes Major Conclusions 
Diabetes 
Prevention 
Program 
(DPP)15 
Randomized 
controlled 
clinical trial 
-Standard lifestyle 
intervention plus 
placebo (1082) 
-Standard lifestyle 
intervention plus 
Metformin (1073) 
-Intensive lifestyle 
modification 
program (1079) 
 
1996 – 2001 
Average follow up 
of 2.8 years 
 
27 Centers 
Inclusion Criteria: 
- Age > 25 years 
-BMI > 24 (>22 in Asians) 
-Fasting plasma glucose 
concentration 95 – 125 mg/dL or 
OGTT (after 75 g oral glucose 
load) 140 – 199 mg/dL 
Primary questions: 
-Does a lifestyle 
intervention vs 
treatment with 
Metformin prevent or 
delay the onset of 
diabetes?   
-Do these two 
interventions differ in 
effectiveness? 
-Does their 
effectiveness differ 
according to age, sex 
or race/ethnic group 
Diabetes crude incidence (per 100 
person years):  
11.0 for placebo 
7.8 for metformin 
4.8 for lifestyle 
 
Diabetes incidence reduced by: 
58% in lifestyle (95% CI, 48-66%) 
31% with Metformin (95% CI, 17-
43%) 
 
Effects were similar for sex and in 
all racial and ethnic groups  
 
*Over 100 publications have resulted 
from this study 
Exclusion Criteria: 
-Those taking any medications 
known to alter glucose 
metabolism  
-Any illnesses that could reduce 
life expectancy or ability to 
participate in the trial 
Diabetes 
Prevention 
Program 
Outcomes 
Study 
(DPPOS)6,24 
Ongoing 
observational 
study 
Follow up of same 
groups as above 
(2776 88% of DPP) 
-Placebo (935) 
-Metformin (926) 
-Lifestyle (915) 
 
2002 – 2013 
Average follow up 
of 5.7 years 
 
 
 
Same as above Assessment of 
incident diabetes risk 
in subjects with 
normal glucose 
regulation vs 
prediabetic 
 
56% lower diabetes risk in those 
who returned to normal glucose 
regulation than those who remained 
prediabetic (p<0.0001); unaffected 
by group assignment 
 
In women lifestyle intervention 
decreased microvascular disease by 
21% when compared to placebo and 
22% when compared to Metformin 
Participants who did not develop 
diabetes during follow up had a 25% 
lower aggregate microvascular 
disease prevalence 
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Study 
 
Study  
Type 
Treatment (n); 
study duration 
Major Criteria  
for Enrollment: 
Outcomes Major Conclusions 
Look 
AHEAD 
(Action for 
Health in 
Diabetes)44 
Randomized 
controlled trial 
-Diabetes Support 
and Education 
(control) (2575) 
-Lifestyle 
intervention group 
(2570) 
 
2001 – 2012 
Average follow up 
of 9.6 years 
 
16 Centers 
Inclusion Criteria: 
-45-75 years of age 
-Self-reported T2DM as verified 
by use of glucose lowering 
medications, physicians report or 
glucose levels 
-BMI > 25 
-A1C ≤11% 
-Systolic BP < 160 mmHg 
-Diastolic BP < 100 mmHg 
-Triglyceride < 600 mg/dL 
-Ability to complete a valid 
maximal exercise test 
-Relationship with a primary care 
provider 
Exclusion Criteria: 
-Inadequate control of comorbid 
condition 
-A1C > 11 
-BP ≥ 160/100 mmHg 
-Fasting triglyceride ≥ 600 mg/dL 
-Factors that may limit adherence 
to interventions or affect conduct 
of trial 
-Underlying diseases that may 
limit lifespan and/or affect the 
safety of the interventions 
Primary: 
-A composite that 
included death from 
cardiovascular 
causes, non-fatal MI, 
non-fatal stroke 
(p=0.51) 
 
Secondary: 
-Primary plus 
hospitalization for 
angina (p=0.23) 
-Above plus CABG, 
PCI, hospitalization 
for heart failure, 
carotid endartectomy, 
or peripheral vascular 
disease (p=0.29) 
Intensive lifestyle intervention, with 
focus on weight loss, does not reduce 
the rate of cardiovascular events in 
overweight adults with T2DM 
CI: Confidence Interval; MI: Myocardial Infarction; PCI: Percutaneous Interventions; CABG: Coronary Artery Bypass Graft
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APPENDIX 4 
etfor in se in Prediabetic Adolescents 
Authors 
Year 
Location 
Study type Treatment (n); 
 study duration 
Main inclusion criteria Objectives Key findings 
Srivivasan 
et al .82 
2006 
Australia 
Double blind, 
randomized 
placebo 
controlled, 
cross over 
trial 
Metformin 2000 mg/day 
(10) 
Placebo (12) 
 
Metformin and placebo 
for 6 months each with a 
2 week washout period 
-9-18 year olds 
-Clinical suspicion of insulin 
resistance with either: 
     -Fasting insulin to glucose ratio  
     -Presence of acanthosis nigricans 
 
-64% high prevalence ethnic 
background 
-25% northern European background 
-11% mixed background 
Examination of 
Metformin’s effects on 
body composition and 
insulin sensitivity  
Good safety profile 
Metformin greater than placebo 
for fasting serum glucose, 
fasting insulin 
Metformin beneficial for 
weight, BMI, waist 
circumference, subcutaneous 
abdominal fat (MRI) 
Freemark 
et al.83 
2001 
USA 
Randomized, 
double blind, 
placebo 
controlled 
trial 
Metformin 1000 mg/day 
(14) 
Placebo (15) 
 
6 months 
-12-19 year olds 
-BMI > 30 kg/m2 
-Fasting insulin > 15µU/ml  
-At least 1 first or second degree 
relative with T2DM 
 
-Black (45%) and white (55%) 
Examination of the 
effects of Metformin on 
BMI, serum leptin, 
glucose tolerance and 
serum lipids in those 
with hyperinsulinemia 
and family history of 
T2DM 
Well tolerated 
Significant improvement in 
insulin and glucose with 
Metformin 
Metformin significantly 
decreased BMI SDS 
Kendall et 
al.33 
2013 
UK 
Double blind 
placebo 
controlled 
parallel group 
trial 
Metformin 1500 mg/day 
(74) 
Placebo (77) 
 
6 months 
-BMI > 98th percentile (UK) 
-Impaired glucose tolerance (OGTT 
7.8-11.1) +/- IFG ≥ 6.1-≤7.0 or 
-Hyperinsulinemia 
 
-British white (76%), British Asian 
(22.5%) and Afro-Caribbean (.01%)  
Examination of the 
effect of Metformin on 
BMI SD score, 
metabolic risk factors 
and adipokines 
Good safety 
Decreased fasting glucose, 
significant at 3 months but not 
6 mg 
Metformin significant decrease 
in BMI SDS, BMI and weight; 
ALT improvement at 3 months, 
but not 6 months 
 
Kay et 
al.84 
Randomized, 
double blind 
Metformin 1700 mg/day 
(12) 
-BMI > 30 kg/m2 
-Hyperinsulinemia 
Examination of the 
effects of Metformin on 
Increased weight loss, 
decreased body fat, increased 
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Authors 
Year 
Location 
Study type Treatment (n); 
 study duration 
Main inclusion criteria Objectives Key findings 
2001 
USA 
placebo 
controlled 
trial 
Placebo (12) 
 
8 weeks 
 
 
-All caucasian 
decreasing 
hyperinsulinemia, insulin 
resistance and adiposity 
fat free mass to body fat ratio 
(bioelectrical impedance) and 
greater insulin response on 
Metformin  
Atabek et 
al.85 
2008 
Turkey 
Randomized, 
double blind 
placebo 
controlled 
Metformin 1000mg/day 
(90) 
Placebo (30) 
 
6 months 
-9-17 year olds 
-Hyperinsulinemia 
-BMI > 95th percentile (CDC) 
Examination of whether 
Metformin treatment was 
effective in reducing 
body weight and 
hyperinsulinemia and 
ameliorating insulin 
sensitivity indices 
Significant weight loss, 
decreased BMI and insulin 
concentration on Metformin 
Significant decrease in HOMA-
IR and QUICKI 
Fu et al.86 
2007 
China 
Clinical Trial Metformin 1000mg/day 
(30) 
No control group 
 
3 months 
-7-16 year olds 
-Healthy subjects with weight > 97th 
percentile and Exceeded 30% 
(moderately obese) or 50% (severely 
obese) standard weight for age and 
sex (1995 national reference criteria) 
-Impaired glucose tolerance 
Evaluation of the 
prevalence of metabolic 
syndrome and 
comparison of risk 
factors such as insulin 
resistance, adiponectin 
levels and impaired 
glucose tolerance 
Significant improvement in 
BMI, blood pressure, IGT 
status, lipids and HOMA-IR 
Gomez-
Diaz et 
al.87 
2012 
Mexico 
Randomized, 
double blind, 
placebo 
controlled 
trial 
Metformin 1700 mg/day 
(28) 
Placebo (24) 
 
3 months 
-Insured 4-17 year olds 
-Impaired glucose tolerance 
Examination of the 
effects of Metformin on 
the concentration of 
resistin and other makers 
of insulin resistance or 
inflammation in youth 
with glucose intolerance 
Significant improvements in 
A1C, HOMA-IR on Metformin 
Nadeau et 
al.88 
2008 
USA 
Randomized, 
double blind, 
placebo 
controlled 
trial 
Metformin 1700mg/day 
(37) 
Placebo (13) 
 
6 months 
 
 
-Hyperinsulinemia  
Two of the following: 
-Acanthosis nigricans 
-BMI >30 kg/m2 or >95th % for age 
-Family history of T2DM 
 
-African American (30%), Hispanic 
(58%), Caucasian (4%), Native 
Examination of the 
effects of Metformin and 
lifestyle on insulin 
resistance, fatty liver and 
liver associated enzymes 
Well tolerated 
Significantly lower fasting 
insulin, fatty liver score and 
prevalence of steatosis on 
Metformin 
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Authors 
Year 
Location 
Study type Treatment (n); 
 study duration 
Main inclusion criteria Objectives Key findings 
American (6%), Asian/Pacific 
Islander (2%) 
Love-
Osborne 
et al.55 
2008 
USA 
Randomized, 
double blind, 
placebo 
controlled 
trial 
Metformin 1700 mg/day 
(60) 
Placebo (25) 
 
6 months 
Focus on goal setting 
 
-12-19 year olds 
-Hyperinsulinema 
Two of the following: 
-Acanthosis nigricans 
-BMI >95th % 
-Family history of T2DM 
 
-Hispanic (56%), African American 
(34%) and Other (10%) 
Examination of whether 
Metformin and goal 
setting improves weight 
loss and clinical status in 
obese adolescents 
No overall difference in weight 
loss  
More subjects taking 
Metformin decreased BMI by 
>5% 
Females on Metformin were 
more likely to decrease BMI 
than males 
BMI SDS: Body Mass Index Standard Deviation Score; QUICKI: Quantitative Insulin-Sensitivity Check Index  
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LIST OF JOURNAL ABBREVIATIONS 
BMC Public Health BMC Public Health 
BMJ B?????ritish Medical Journal 
Can J Diabetes Canadian Journal of Diabetes 
Child Obes Print Childhood Obesity 
Clin Biochem Rev The Clinical Biochemist Reviews 
Control Clin Trials Controlled Clinical Trials 
Curr Diab Rep Current Diabetes Reports 
Diabet Med J Br 
Diabet Assoc 
Diabetes Medicine  
A Journal of the British Diabetes Association 
Diabet Res Clin Pract Diabetes Research and Clinical Practice 
Endocrinol Metab Clin 
North Am 
Endocrinology and Metabolism Clinics of North America 
Endocr Pract Off J Am 
Coll Endocrinol Am 
Assoc Clin Endocrinol 
Endocrine Practice 
Endocr Res Endocrine Research 
EJE European Journal of Endocrinology 
Int J Endocrinol International Journal of Endocrinology 
JACC Journal of the American College of Cardiology 
JAMA ??????The Journal of the American Medical Association 
JAMA Pediatr ???? Pediatrics 
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J Am Diet Assoc Journal of the American Dietetic Association 
JCEM Journal of Clinical Endocrinology and Metabolism 
JCH The Journal of Clinical Hypertension (JCH) 
J Pediatr The Journal of Pediatrics 
Med Sci Sports Exer Medicine and Science in Sport and Exercise 
NEJM New England Journal of Medicine 
Obes Silver Spring Md Obesity 
Obes Rev Off J Int 
Assoc Study Obes 
Obesity Reviews 
Pediatr Diabetes Pediatric Diabetes 
Pediatr Res Pediatric Research 
Perm J The Permanente Journal 
Popul Health Manag Population Health Management 
PMJ Postgraduate Medical Journal 
Strength Cond Res The Journal of Strength and Conditioning Research 
Univ West Ont Med J University of Western Ontario Medical Journal 
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